

Biologics AND Biosimilars

► What Matters to Physicians?

Anna L. Molinari¹, Arturo Loaiza-Bonilla, M.D.², David Charles, M.D.¹

INTRODUCTION

STUDY OBJECTIVES


Assess physicians' familiarity and comfort level with prescribing biologics and switching patients between biologic and biosimilar therapies.

Assess the adequacy of government-run pharmacovigilance systems in informing physicians of pertinent safety and efficacy information on biologic therapies.


METHODS

Physicians in the European Union (n=502) completed an electronic survey on the SERMO app and website. The survey was available from February 14-15, 2017.

Survey Participants' HOME COUNTRIES



Survey Participants' MEDICAL SPECIALTIES





RESULTS

SWITCHING

Only 12% of Physicians Responded That the Most Important Factor in Determining Whether a Patient Should Be Switched is the Cost to Payers.

33% Physicians Responded they were Uncomfortable with Switching Patients Multiple Times.



PHARMACOVIGILANCE

84% of Physicians Responded That They Were Not Very Confident or Only Somewhat Confident in Government-Run Pharmacovigilance Systems

84% Not Very Confident or only Somewhat Confident

16% Very Confident

CONCLUSIONS

CRITICAL FINDINGS

The safety and efficacy of biologic and biosimilar medicines is of paramount importance to physicians when it comes to switching.

Physicians do not completely trust government-run pharmacovigilance systems.

RECOMMENDATIONS FOR FUTURE EFFORTS

Provide physicians with easy access to current clinical information on biologic therapies, including therapeutic guidelines, clinical trial results, and adverse effects.

- Include more sessions on biologic therapies at medical conferences.
- Provide more online information on biologic therapies on medical societies' websites.
- Create continuing medical education content specifically focused on biologic therapies.

Improve government-run pharmacovigilance systems so that physicians receive the information they need to confidently manage patients on biologic therapies.

ACKNOWLEDGEMENTS & DISCLOSURES



The Global Alliance for Patient Access (GAfPA) is an international network of physicians and patient representatives dedicated to ensuring patient access to approved therapies and appropriate clinical care. GAfPA accomplishes this mission by recruiting, training and mobilizing policy-minded physicians and patient advocacy groups to be effective advocates for patient access. Their unique insight can guide policymakers to make informed decisions about value, safety, cost and, ultimately, patient access. In addition to hosting international workshops for physicians and patient groups to educate attendees on important global policies that threaten patient access to biologics or pose risks to patient safety, GAfPA helps distribute educational materials on key health policy issues. For more information, please visit www.gaipa.org

Disclosures: Vanderbilt University Medical Center receives income from Allergan, Ipsen, Merz, Intec, Medtronic, Lundbeck, USWorldmeds, Boston Scientific, and St. Jude for research or educational programs led by Dr. Charles. Dr. Charles receives income from Allergan, Ipsen, and Revance for consulting services. Ms. Molinari and Dr. Bonilla have no conflicts to disclose.

Acknowledgement: This data was generated from a SERMO Poll. SERMO is the largest global social network exclusively for doctors.

¹Global Alliance for Patient Access, Washington, DC USA
²Cancer Treatment Centers of America, Philadelphia, PA USA